A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Exclusion Criteria

• •1. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Palliative radiotherapy or traditional Chinese medicine with anti-tumor indications within 2 weeks before the first dose;
• •2. History of severe heart disease;
• •3. QT prolongation, complete left bundle branch block, III degree atrioventricular block;
• •4. Active autoimmune and inflammatory diseases;
• •5. Other malignant tumors diagnosed within 5 years before the first dose;
• •6. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg);
• •7. Patients with poor glycemic control or with diabetic gangrene;
• •8. A history of ILD requiring steroid therapy or current ILD or grade ≥2 radiation pneumonitis;
• •9. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
• •10. Patients with central nervous system involvement;
• •11. Had a history of or central nervous system disease;
• •12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any component of BL-M08D1 excipients;
• •13. Received previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
• •14. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;
• •15. Active infection requiring systemic therapy within 4 weeks before the first dose of study drug;
• •16. Pleural, abdominal, pelvic or pericardial effusion requiring drainage and/or with symptoms within 4 weeks before the first dose of study drug;
• •17. Received another trial drug 4 weeks or 5 half-lives before the first dose;
• •18. Pregnant or lactating women;
• •19. Other conditions for participation in the trial were not considered appropriate by the investigator.